WO2012047763A3 - Stimulation of neuroregeneration by flavonoid glycosides - Google Patents

Stimulation of neuroregeneration by flavonoid glycosides Download PDF

Info

Publication number
WO2012047763A3
WO2012047763A3 PCT/US2011/054377 US2011054377W WO2012047763A3 WO 2012047763 A3 WO2012047763 A3 WO 2012047763A3 US 2011054377 W US2011054377 W US 2011054377W WO 2012047763 A3 WO2012047763 A3 WO 2012047763A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuroregeneration
stimulation
flavonoid glycosides
flavonoid
glycosides
Prior art date
Application number
PCT/US2011/054377
Other languages
French (fr)
Other versions
WO2012047763A2 (en
Inventor
Marcy Zenobi-Wong
Original Assignee
Marcy Zenobi-Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marcy Zenobi-Wong filed Critical Marcy Zenobi-Wong
Priority to JP2013532850A priority Critical patent/JP2014506868A/en
Priority to EP11831371.7A priority patent/EP2624816A2/en
Publication of WO2012047763A2 publication Critical patent/WO2012047763A2/en
Publication of WO2012047763A3 publication Critical patent/WO2012047763A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.
PCT/US2011/054377 2010-10-07 2011-09-30 Stimulation of neuroregeneration by flavonoid glycosides WO2012047763A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2013532850A JP2014506868A (en) 2010-10-07 2011-09-30 Stimulation of neurogenesis by flavonoid glycosides
EP11831371.7A EP2624816A2 (en) 2010-10-07 2011-09-30 Stimulation of neuroregeneration by flavonoid glycosides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39101810P 2010-10-07 2010-10-07
US61/391,018 2010-10-07

Publications (2)

Publication Number Publication Date
WO2012047763A2 WO2012047763A2 (en) 2012-04-12
WO2012047763A3 true WO2012047763A3 (en) 2013-10-24

Family

ID=45925327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/054377 WO2012047763A2 (en) 2010-10-07 2011-09-30 Stimulation of neuroregeneration by flavonoid glycosides

Country Status (4)

Country Link
US (1) US20120087980A1 (en)
EP (1) EP2624816A2 (en)
JP (1) JP2014506868A (en)
WO (1) WO2012047763A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140107193A1 (en) * 2011-10-14 2014-04-17 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of kaempferol and/or fisetin and uses thereof
WO2016176687A2 (en) * 2015-04-30 2016-11-03 President And Fellows Of Harvard College Rna and protein networks that locally control brain wiring during development

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080044390A1 (en) * 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092324A1 (en) * 2004-03-19 2005-10-06 The Trustees Of Columbia University In The City Of New York Ginkgolide compounds, compositions, extracts, and uses thereof
US7442394B2 (en) * 2005-05-02 2008-10-28 University Of South Florida Combined effects of nutrients on proliferation of stem cells
US20080241211A1 (en) * 2007-03-27 2008-10-02 University Of Southern California Device which enhances the biological activity of locally applied growth factors with particular emphasis on those used for bone repair

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
US20080044390A1 (en) * 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AN ET AL.: "The total flavonoids extracted from Xiaobuxin-Tang up-regulate the decreased hippocampal neurogenesis and neurotrophic molecules expression in chronically stressed rats.", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, vol. 32, no. 6, 2008, pages 1484 - 1490, XP023181326, DOI: doi:10.1016/j.pnpbp.2008.05.005 *

Also Published As

Publication number Publication date
US20120087980A1 (en) 2012-04-12
JP2014506868A (en) 2014-03-20
WO2012047763A2 (en) 2012-04-12
EP2624816A2 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
WO2010083170A3 (en) Cell stimulation using quantum dots
WO2014124087A8 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
WO2012061744A3 (en) Stabilized step function opsin proteins and methods of using the same
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
WO2010028152A3 (en) Systems, devices and methods for the treatment of tinnitus
WO2012058494A3 (en) Isoprene synthase variants for improved production of isoprene
WO2011127088A3 (en) Methods and compositions for decreasing chronic pain
CA3070606A1 (en) Compositions and methods for increasing phytochemical bioavailablity and bioactivity
MX351083B (en) Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers.
WO2012047733A3 (en) Treatment of acne by conditioned media
IN2015DN02826A (en)
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2011138786A3 (en) Stem cell bank for personalized medicine
WO2012098537A8 (en) Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
WO2013021279A3 (en) Highly galactosylated antibodies
MX367670B (en) Chromophore combinations for biophotonic uses.
AU2010236286A8 (en) Modulation of inflammatory responses by Factor XI
WO2012118988A8 (en) Direct reprogramming of human fibroblasts to functional neurons under defined conditions
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2012112419A8 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
MY182946A (en) Production of organic acids by fermentation at low ph
WO2012119209A3 (en) Game pieces
WO2011121051A3 (en) Preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the argania tree, use thereof for treating skin ageing, inflammation and scarring, and production thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831371

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011831371

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013532850

Country of ref document: JP

Kind code of ref document: A